Literature DB >> 10720928

Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses.

S C Cannon1.   

Abstract

Several heritable forms of myotonia and periodic paralysis are caused by missense mutations in the voltage-gated sodium channel of skeletal muscle. Mutations produce gain-of-function defects, either disrupted inactivation or enhanced activation. Both defects result in too much inward Na current which may either initiate pathologic bursts of action potentials (myotonia) or cause flaccid paralysis by depolarizing fibers to a refractory inexcitable state. Myotonic stiffness and periodic paralysis occur as paroxysmal attacks often triggered by environmental factors such as serum K+, cold, or exercise. Many gaps remain in our understanding of the interactions between genetic predisposition and these environmental influences. Targeted gene manipulation in animals may provide the tools to fill in these gaps.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720928     DOI: 10.1046/j.1523-1755.2000.00914.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

1.  Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus.

Authors:  R H Wallace; I E Scheffer; S Barnett; M Richards; L Dibbens; R R Desai; T Lerman-Sagie; D Lev; A Mazarib; N Brand; B Ben-Zeev; I Goikhman; R Singh; G Kremmidiotis; A Gardner; G R Sutherland; A L George; J C Mulley; S F Berkovic
Journal:  Am J Hum Genet       Date:  2001-03-13       Impact factor: 11.025

2.  The human skeletal muscle Na channel mutation R669H associated with hypokalemic periodic paralysis enhances slow inactivation.

Authors:  A F Struyk; K A Scoggan; D E Bulman; S C Cannon
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

3.  Functional effects of two voltage-gated sodium channel mutations that cause generalized epilepsy with febrile seizures plus type 2.

Authors:  J Spampanato; A Escayg; M H Meisler; A L Goldin
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

4.  Neuropathology in Drosophila membrane excitability mutants.

Authors:  Tim Fergestad; Barry Ganetzky; Michael J Palladino
Journal:  Genetics       Date:  2005-11-04       Impact factor: 4.562

5.  K-aggravated myotonia mutations at residue G1306 differentially alter deactivation gating of human skeletal muscle sodium channels.

Authors:  James R Groome; Esther Fujimoto; Peter C Ruben
Journal:  Cell Mol Neurobiol       Date:  2005-11       Impact factor: 5.046

6.  The dominant cold-sensitive Out-cold mutants of Drosophila melanogaster have novel missense mutations in the voltage-gated sodium channel gene paralytic.

Authors:  Helen A Lindsay; Richard Baines; Richard ffrench-Constant; Kathryn Lilley; Howard T Jacobs; Kevin M C O'Dell
Journal:  Genetics       Date:  2008-08-24       Impact factor: 4.562

7.  Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin huwentoxin-IV (μ-TRTX-Hh2a).

Authors:  Natali A Minassian; Alan Gibbs; Amy Y Shih; Yi Liu; Robert A Neff; Steven W Sutton; Tara Mirzadegan; Judith Connor; Ross Fellows; Matthew Husovsky; Serena Nelson; Michael J Hunter; Mack Flinspach; Alan D Wickenden
Journal:  J Biol Chem       Date:  2013-06-12       Impact factor: 5.157

Review 8.  Subtype-selective targeting of voltage-gated sodium channels.

Authors:  Steve England; Marcel J de Groot
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

9.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

10.  Clinical Diversity of SCN4A-Mutation-Associated Skeletal Muscle Sodium Channelopathy.

Authors:  Sang-Chan Lee; Hyang-Sook Kim; Yeong-Eun Park; Young-Chul Choi; Kyu-Hyun Park; Dae-Seong Kim
Journal:  J Clin Neurol       Date:  2009-12-31       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.